Background: Hemorrhagic cystitis (HC) is one of the most challenging complications in hematopoietic stem cell transplantation (HSCT). Estrogen is one of the suggested treatments for controlling this problem.
INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is a significant step in the management of hematologic disorders. High-dose myeloablative chemotherapy prior to HSCT is required which can lead to various adverse effects. 1 One of the most serious complications following HSCT is hemorrhagic cystitis (HC). 2, 3 Most common causes of HC include chemotherapeutic agents (e.g. cyclophosphamide, isofosfamide, and busulfan), viral infections, graft versus host disease (GVHD), and irradiation. HC occurs in 10 to 40 percent of patients who receive high-dose chemotherapies. 4 Bleeding, as a common manifestation of HC, is graded as mild, moderate, and severe. Severe HC can be life threatening and hemodynamic stability should be monitored. 5, 6 Considering the time of occurrence, HC is categorized in two entities. HC that initiates within a few days after transplantation is considered as early-onset, while late-onset HC occurs after 7 days. 7, 8 Early-onset HC is usually attributed to cyclophosphamide, and late-onset HC is generally due to viral infections. 9 The management of HC includes hydration, bladder irrigation, pain control, and antiviral agents. Use of formalin, prostaglandin E1, factor VIIa, factor XIII, hyperbaric oxygen,
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International Journal of Hematology Oncology and Stem Cell Research ijhoscr.tums.ac.ir intravesicular sodium hyaluronate and recombinant human epidermal growth factor is still controversial in the HC treatment. [9] [10] [11] [12] In addition, some studies have suggested that conjugated estrogen can be an effective option in the management of HC for HSCT patients; however, its mechanism of action is unclear. [13] [14] [15] This study aimed to assess the effects of estrogen on the control of bleeding in HSCT patients who suffer from late-onset HC.
SUBJECTS AND METHODS Design and setting
This case-control randomized clinical trial study was conducted at the Hematology-Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences (TUMS), Tehran, Iran. The study protocol, methods of data collection and analysis were approved by the institutional review board. All the enrolled patients provided written informed consent the study protocol according to the declaration of Helsinki before any study-related interventions.
Patients
Adult patients undergoing allogenic HSCT with lateonset HC were enrolled in the study. Patients receiving conditioning regimen, myeloablative chemotherapy (busulfan and cyclophosphamide) or nonmyeloablative chemotherapy (busulfan and fludarabine) were included. Whereas, patients with bacterial urinary tract infections, platelet count less than 20,000 per μL, prothrombin time longer than 14 seconds, partial thromboplastin time longer than 36 seconds, active hepatic disease (i.e. bilirubin more than 3.0 mg per dL, AST or ALT more than 2 times above the upper limit of normal), nephrolithiasis, history or high risk of venous thromboembolism, and triglycerides more than 300 mg per dL were excluded.
Interventions
Patients were randomly assigned to the drug or control group based on the balanced block randomization. All patients received the standard treatments of HC, including oral or intravenous hydration, bladder irrigation, urinary catheterization or diuretics. In the drug group, patients received 6.25 mg conjugated estrogen oral tablets in a daily single dose continued up to the resolution of hematuria. Patients were followed regularly for 100 days after HSCT.
Outcomes
Patients' demographic characteristics, physical exam, and laboratory data were recorded. Laboratory data including complete blood count (CBC), liver function tests (LFTs), and urine analysis (UA), tested at baseline, and then weekly. Grading system of Bearman et al was used to classify the bleeding severity of HC. Adverse reactions due to conjugated estrogen were assessed. Time to down stage and time to complete response (CR) were the main outcome indicators.
Statistical analysis
Mann-Whitney U test and Chi-square test were used to compare continues and categorical variables between two groups, respectively. Probability of complete response and down stage was calculated by Kaplan-Meier estimator and compared between groups by log-rank test. Proportional Cox regression model was used to compare groups adjusted for different baseline characteristics (such as HC grades). Statistical analysis was performed by SPSS version 17 (SPSS Inc, Chicago, IL, USA). P-value of ≤ 0.05 was defined as the level of significance.
RESULTS
During the two-year study period, 56 patients met the inclusion criteria. Among them 25 patients entered the drug group (13 males, 12 females) and 31 patients entered the control group (21 males, 10 females). Patients' characteristics and HC clinical data are summarized in Table 1 . Mean age of patients in drug group was 25 years, ranging from 8 to 51 years and in control group was 27, ranging from 10 to 46 years. The median time of HC onset was 37 days after HSCT in drug group (range 8-72 days) and 40 days in the control group (range 14-94 days) ( Table 1) . Duration of conjugated estrogen administration was from 5 to 38 days with the average of 14 days. Among the study patients, 55 patients underwent human leukocyte antigen (HLA) 15 Table 3 ). Probability of complete response by groups adjusted for baseline HC grade 2 is shown in Figure 1 and the probability of down stage by groups adjusted for baseline HC grade 2 is demonstrated in Figure 2 .
On the 25 th day of HC, no significant difference was seen in the down stage rates [drug group: 82%, control group: 87.1% (p=0.33)]. However, the complete response rate was significantly different between two groups [drug group: 37.1%, the control group: 58.1% (p=0.024)]. During the study period, six patients died, three in each group. However, the mortalities were due to GVHD or relapse of underlying disease and not related to HC. No adverse drug reactions were detected from conjugated estrogen during study period. 
DISCUSSION
Hemorrhagic cystitis is a major problem for patients undergoing HSCT which might lead to death. 16 Although different factors are involved in the pathogenesis of late-onset HC, the etiology is not clearly understood yet. 17 Possible risk factors are viral infections (like adenoviruses, [18] [19] [20] polyomavirus, 21 and cytomegaloviruses 22 ), graft versus host disease 23 and thrombocytopenia. 17 Although prevention is the key strategy for HC management in chemotherapy procedures, there are some medical interventions as well. Patients should be treated with hydration and forced diuresis. Pain is managed by analgesics such as narcotics and spasmolytics. In grade 3 HC, bladder irrigation is necessary to prevent bladder tamponade. HC with obstructive symptoms is an emergency condition and should be treated with an invasive procedure including blood clot evacuation. Intravesicular modalities like Alum infusion, formalin, phenol in various concentrations may also be used. 11, [24] [25] [26] [27] [28] Hydronephrosis and urethral stricture were reported as the complications of latter methods. 29 Some studies suggested that the use of rh GM-CSF, sodium hyaluronate, and progtoglandin E1 could be successful options, even though safety and efficacy of none of them have been established. [9] [10] [11] [12] Another proposed treatment alternative for HC is conjugated estrogen, based on some reports. Estrogen may have effects on the microvascular stabilization in the bladder wall. 9, [13] [14] [15] In this study, conjugated estrogen showed no beneficial effect in the treatment of HC associated with HSCT. However, several previous studies have reported improving effects of estrogen on HC. In 1990, Liu et al. reported five patients successfully been treated with intraveneous and oral estrogen with no adverse reactions although thrombosis was reported as the main risk. 13 Miller et al. documented a complete remission rate of 86% (6 of 7 patients) with oral estrogen.
14 In another study published by Ordemann et al. 7 out of 10 adult patients (70%) demonstrated positive outcomes. 15 In a report of 10 children and adolescents treated with estrogen for HC following HSCT, Heath et al. indicated 80% improvement of hematuria, 60% resolution of macroscopic hematuria, without any recurrences. Although estrogen was well tolerated by most patients, one patient developed hepatotoxicity that led to drug discontinuation. 9 Different results of our trial might be due to insufficient dose of conjugated estrogen administered to the patients. Moreover, most of the previous studies have initiated the therapy with injectable forms of estrogen that might have been more effective in the rapid management of HC; nevertheless, only the oral form of conjugated estrogen was used in our study.
CONCLUSION
Oral conjugated estrogen was not effective in the treatment of HC associated with HSCT. Larger doses of estrogen and different routes of administrations should be investigated in large randomized placebocontrolled clinical trials to evaluate the safety and efficacy of this drug in the management of HC following HSCT.
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